Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The outbreak of the coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 that has created huge trepidation worldwide, has a mortality rate of 0.5% to 1% and is growing incessantly. There are currently no therapies and/or vaccines that may help abate this viral disease, but the use of masks and social distancing can limit the spread. Boosting immunity has been a simple way to resist viral infection and limit fatalities. In this context, the use of nutraceuticals appears to be a potential panacea. The ability of algae-based nutraceuticals, mainly Spirulina, to boost immunity against viral diseases has already been reported clinically. Spirulina-based nutraceuticals boost the adaptive and innate immunity, and bioactive compounds, such as angiotensin-converting enzyme (ACE) inhibitor peptides, phycobiliproteins, sulfated polysaccharides, and calcium-Spirulan, can serve as antiviral agents. The presence of these molecules indicates its potential role in resisting infection and COVID-19 disease progression. This review focuses on the potential role of algal nutraceuticals as immune boosters to combat the human coronavirus and other viral diseases. The potential use of Spirulina-based nutraceuticals for combating COVID-19, its mechanism, and future directions have also been discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405 · cited 2×
“[6] identified 67 druggable host proteins targeted by 69 existing U.”
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445 · cited 1×
“The most common lethality in coronavirus infections and COVID19 is associated with underlying lung injury due to the downregulation of ACE2 [38,43].”
Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05985-9 · Cited by 2,684
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912 · cited 4×
“Acute respiratory distress syndrome in severe cases of coronavirus infections is generally a result of cytokine release syndrome (CRS) and secondary hemophagocytic lymphohistiocytosis [1,31].”
InfluentialThe diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients
Yang, A.-P., Liu, J.-P., Tao, W.-Q., & Li, H.-M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106504 · Cited by 1,138 · cited 1×
“NLRP3 inflammasome activation plays an important role in the innate immune response to pathogenic infections in macrophages, including COVID-19 [34,35].”
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Jiang, S., Hillyer, C., & Du, L. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.007 · Cited by 847
Bioactivity and applications of sulphated polysaccharides from marine microalgae
Raposo, M., De Morais, R., & Bernardo de Morais, A. (2013) · Marine Drugs · doi:10.3390/md11010233 · Cited by 594
Hypolipidemic, Antioxidant, and Antiinflammatory Activities of Microalgae Spirulina
Deng, R., & Chow, T. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00200.x · Cited by 435
Research works printed but not linked: 35
- Liu, 2020, Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases, ACS Cent Sci, 6, 315, 10.1021/acscentsci.0c00272 · DOI · Paper page
- Wadman, 2020, A rampage through the body, Science, 368, 356, 10.1126/science.368.6489.356 · doi:10.1126/science.368.6489.356
- Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 10.1016/j.cell.2020.02.052 · DOI · Paper page
- Thanh Le, 2020, The COVID-19 vaccine development landscape, Nat Rev Drug Discov, 19, 305, 10.1038/d41573-020-00073-5 · DOI · Paper page
- McCarty, 2020, Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus, Prog Cardiovasc Dis, 63, 383, 10.1016/j.pcad.2020.02.007 · DOI · Paper page
- Muscogiuri, 2020, Nutritional recommendations for COVID-19 quarantine, Eur J Clin Nutr, 74, 850, 10.1038/s41430-020-0635-2 · DOI · Paper page
- Caccialanza, 2020, Early nutritional supplementation in non-critically ill patients hospitalized for the 2019 novel coronavirus disease (COVID-19): Rationale and feasibility of a shared pragmatic protocol, Nutrition, 74, 10.1016/j.nut.2020.110835 · DOI · Paper page
- Laviano, 2020, Nutrition support in the time of SARS-CoV-2 (COVID-19), Nutrition, 74, 10.1016/j.nut.2020.110834 · DOI · Paper page
- Brown, 2014, Seaweed and human health, Nutr Rev, 72, 205, 10.1111/nure.12091 · DOI · Paper page
- Cicero, 2017, Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel, Nutr Rev, 75, 731, 10.1093/nutrit/nux047 · DOI · Paper page
- Gupta, 2013, New insights into the biodiversity and applications of cyanobacteria (blue-green algae)—Prospects and challenges, Algal Res, 2, 79, 10.1016/j.algal.2013.01.006 · DOI · Paper page
- Mogany, 2019, Extraction and characterisation of analytical grade C-phycocyanin from Euhalothece sp, J Appl Phycol, 31, 1661, 10.1007/s10811-018-1661-5 · DOI
- Chei, 2020, Spirulina maxima extract prevents activation of the NLRP3 inflammasome by inhibiting ERK signaling, Sci Rep, 10, 2075, 10.1038/s41598-020-58896-6 · DOI · Paper page
- Furukawa, 2008, Preventive or therapeutic composition for viral infectious disease, Google Patents;
- Schaeffer, 2000, Anti-HIV activity of extracts and compounds from algae and cyanobacteria, Ecotoxicol Environ Safe, 45, 208, 10.1006/eesa.1999.1862 · DOI · Paper page
- Wu, 2016, The antioxidant, immunomodulatory, and anti-inflammatory activities of Spirulina: An overview, Arch Toxicol, 90, 1817, 10.1007/s00204-016-1744-5 · DOI · Paper page
- Ranga Rao, 2013, In vivo bioavailability and antioxidant activity of carotenoids from microalgal biomass — A repeated dose study, Food Res Int, 54, 711, 10.1016/j.foodres.2013.07.067 · DOI
- Mah, 2016, Metabolic regulation of natural killer cell IFN-γ production, Crit Rev Immunol, 36, 131, 10.1615/CritRevImmunol.2016017387 · DOI · Paper page
- Nishida, 2019, Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments, Medicine (Baltimore), 98, 10.1097/MD.0000000000016771 · DOI
- Shi, 2020, COVID-19 infection: The perspectives on immune responses, Cell Death Differ, 27, 1451, 10.1038/s41418-020-0530-3 · DOI · Paper page
- Zhang, 2020, COVID-19: Melatonin as a potential adjuvant treatment, Life Sci, 250, 10.1016/j.lfs.2020.117583 · DOI · Paper page
- Li, 2020, Coronavirus infections and immune responses, J Med Virol, 92, 424, 10.1002/jmv.25685 · DOI · Paper page
- Yuen, 2020, SARS-CoV-2 and COVID-19: The most important research questions, Cell Biosci, 10, 40, 10.1186/s13578-020-00404-4 · DOI · Paper page
- Khafaga, 2018, Spirulina ameliorates methotrexate hepatotoxicity via antioxidant, immune stimulation, and proinflammatory cytokines and apoptotic proteins modulation, Life Sci, 196, 9, 10.1016/j.lfs.2018.01.010 · DOI
- Kuster, 2020, SARS-CoV2: Should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?, Eur Heart J, 41, 1801, 10.1093/eurheartj/ehaa235 · DOI · Paper page
- Adedeji, 2013, Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms, J Virol, 87, 8017, 10.1128/JVI.00998-13 · DOI · Paper page
- Imai, 2010, Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis, Circ J, 74, 405, 10.1253/circj.CJ-10-0045 · DOI · Paper page
- Fang, 2020, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Resp Med, 8, e21, 10.1016/S2213-2600(20)30116-8 · DOI · Paper page
- Rico-Mesa, 2020, Outcomes in patients with COVID-19 infection taking ACEI/ARB, Curr Cardiol Rep, 22, 31, 10.1007/s11886-020-01291-4 · DOI · Paper page
- Aiello, 2019, Chemical and biological characterization of spirulina protein hydrolysates: Focus on ACE and DPP-IV activities modulation, J Funct Food, 63, 10.1016/j.jff.2019.103592 · DOI · Paper page
- Heo, 2017, A heptameric peptide purified from Spirulina sp. gastrointestinal hydrolysate inhibits angiotensin I-converting enzyme-and angiotensin II-induced vascular dysfunction in human endothelial cells, Int J Mol Med, 39, 1072, 10.3892/ijmm.2017.2941 · DOI · Paper page
- Zheng, 2017, Effects of IQP, VEP and Spirulina platensis hydrolysates on the local kidney renin angiotensin system in spontaneously hypertensive rats, Mol Med Rep, 16, 8485, 10.3892/mmr.2017.7602 · DOI
- He, 2018, Transport of ACE inhibitory peptides Ile-Gln-Pro and Val-Glu-Pro derived from Spirulina platensis across Caco-2 monolayers, J Funct Food, 83, 2586
- Hayashi, 1996, A natural sulfated polysaccharide, calcium Spirulan, isolated from Spirulina platensis: In vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities, AIDS Res Hum Retrov, 12, 1463, 10.1089/aid.1996.12.1463 · DOI
- Qureshi, 1996, Spirulina platensis exposure enhances macrophage phagocytic function in cats, Immunopharmacol Immunotoxicol, 18, 457, 10.3109/08923979609052747 · DOI · Paper page
Cited by
Wide range applications of spirulina: from earth to space missions
Fais, G., Manca, A., Bolognesi, F., Borselli, M., Concas, A., Busutti, M., Broggi, G., Sanna, P., Castillo-Aleman, Y. M., Rivero-Jiménez, R. A., et al. (2022) · Marine Drugs · doi:10.3390/md20050299 · Cited by 98
Antiviral Cyanometabolites—A Review
Mazur-Marzec, H., Cegłowska, M., Konkel, R., & Pyrć, K. (2021) · Biomolecules · doi:10.3390/biom11030474 · Cited by 64
Spirulina/Arthrospira/Limnospira—Three Names of the Single Organism
Sinetova, M. A., Kupriyanova, E. V., & Los, D. A. (2024) · Foods · doi:10.3390/foods13172762 · Cited by 51
Huh, J., Zhang, J., Hauerová, R., Lee, J., Haider, S., Wang, M., Hauer, T., Khan, I. A., Chittiboyina, A. G., & Pugh, N. D. (2022) · Scientific Reports · doi:10.1038/s41598-022-19590-x · Cited by 14
Metadata
- Authors
- Ratha, S. K., Renuka, N., Rawat, I., & Bux, F.
- Venue
- Nutrition
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 83
- Pages
- 111089
- ISSN
- 0899-9007 (ISSN-L)
- OpenAlex
- W3109760714
- Cited by
- 70
- References
- 17
- FWCI
- 7.70
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Durban University of Technology
- National Research Foundation (UID 84166)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases. https://app.cochat.ai/papers/10.1016/j.nut.2020.111089
- The paper
- Ratha, S. K., Renuka, N., Rawat, I., & Bux, F. (2021). Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases. Nutrition. https://doi.org/10.1016/j.nut.2020.111089
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.